Anticoagulant compounds, i.e., derivatives of either 4-hydroxycoumarin (e.g., warfarin, bromadiolone) or indane-1,3-dione (e.g., diphacinone, chlorophacinone), have been in worldwide use as rodenticides for Ͼ50 years. These compounds inhibit blood coagulation by repression of the vitamin K reductase reaction (VKOR). Anticoagulant-resistant rodent populations have been reported from many countries and pose a considerable problem for pest control. Resistance is transmitted as an autosomal dominant trait although, until recently, the basic genetic mutation was unknown. Here, we report on the identification of eight different mutations in the VKORC1 gene in resistant laboratory strains of brown rats and house mice and in wild-caught brown rats from various locations in Europe with five of these mutations affecting only two amino acids (Tyr139Cys, Tyr139Ser, Tyr139Phe and Leu128Gln, Leu128Ser). By recombinant expression of VKORC1 constructs in HEK293 cells we demonstrate that mutations at Tyr139 confer resistance to warfarin at variable degrees while the other mutations, in addition, dramatically reduce VKOR activity. Our data strongly argue for at least seven independent mutation events in brown rats and two in mice. They suggest that mutations in VKORC1 are the genetic basis of anticoagulant resistance in wild populations of rodents, although the mutations alone do not explain all aspects of resistance that have been reported. We hypothesize that these mutations, apart from generating structural changes in the VKORC1 protein, may induce compensatory mechanisms to maintain blood clotting. Our findings provide the basis for a DNA-based field monitoring of anticoagulant resistance in rodents.
T HE introduction of warfarin and related anticoaguis an essential cofactor for the post-translational gammalant compounds in the early 1950s produced a sigcarboxylation of several blood coagulation factors nificant change for rodent control practice. The delayed (Nelsestuen et al. 1974; Stenflo et al. 1974; Sadowski action of such compounds, with mortality occurring et al. 1976; Cain et al. 1998 ) and other vitamin-K-dependays or even weeks after initial bait uptake makes them dent proteins (Presnell and Stafford 2002) . During particularly suitable for the control of phobic species each carboxylation step, one molecule of vitamin K hylike brown rats (Rattus norvegicus). Today, control of droquinone is oxidized to vitamin K 2,3 epoxide. The commensal rodents, particularly of brown rats, relies recycling of this micronutrient is achieved by the VKOR, predominantly on the use of anticoagulants.
and suppression of the VKOR by anticoagulants inhibits During the same time period, coumarin derivatives carboxylation of clotting factors and thus compromises have gained a leading role as oral anticoagulants for the the coagulation process. treatment and prevention of thromboembolic events in
In brown rats (R. norvegicus), resistance to the anticohumans. This class of anticoagulants target the vitamin agulants warfarin and diphacinone was first observed in K epoxide reductase (VKOR) complex, which fulfills a 1958 (Boyle 1960) , and warfarin resistance in the house basic function in the recycling of vitamin K (Lowenmouse (Mus musculus/domesticus) was evident shortly thal and Macfarlane 1964). Vitamin K hydroquinone after (Dodsworth 1961) . The majority of reports came from Europe but resistance in commensal rodents was also documented in the United States, Canada, Japan, (1978) ductions in the efficacy of control of rat and mouse expression system and discuss the physiological, evolutionary, and practical implications of the mutations. populations, more potent anticoagulant compounds were developed during the 1970s and 1980s: first difenacoum and bromadiolone, followed later by the more MATERIALS AND METHODS potent "single-feed" compounds brodifacoum, flocoumafen, and difethialone. However, resistance to most Animals: R. norvegicus: Rats of both sexes were analyzed. Animals of the laboratory outbred strains HW and HH were of these compounds was reported soon after their introobtained from two independent laboratory stocks [Central duction (Rowe et al. 1981; Greaves et al. 1982 Blood clotting response test: BCR resistance testing with was found mutated to serine (Tyr139Ser). Mutations warfarin was done as described (Martin et al. 1979) with were absent from the anticoagulant-susceptible backmodifications . BCR testing with ground strains.
bromadiolone was performed according to Gill et al. (1994 . In Germany and Denmark, the test solution was admin-M. musculus/domesticus: Six mice from a colony estabistered by intraperitoneal injection instead of oral application, lished at the CSL in York were found to be homozygous which had proved equally effective (H. J. Pelz, unpublished for a Leu128Ser mutation. Four Reading homozygous data) and is not confounded by any mechanism of reduced resistant mice (MHR) carried the Tyr139Cys mutation intestinal absorption. With each series of tests, the activity of observed before in rats. Neither sequence change was the test solution was checked by including a Wistar albino rat as a known susceptible individual.
seen in the respective background strains. Sequencing DNA sequence determination and mutation screening results are summarized in Table 2 . by ARMS-PCR (that is, wild type for Tyr139), three ani-2). All experiments were run in triplicate to compensate for variation in transfection efficiency. Activity of the mals had no sequence variation in the entire VKORC1 coding region and thus may be regarded as false-positive wild-type protein (0.74 Ϯ 0.23 nmol/mg protein) was set to 100% and was progressively inhibited by warfarin BCR tests. In two animals, a sequence change was found in exon 1, leading to a Ser56Pro exchange. One animal to Ͻ4% at 100 m. The mutation Tyr139Phe displayed an even higher basal activity (116%) and appeared each was homo-and heterozygous, respectively. Ser56-Pro is, therefore, a second candidate mutation in the largely insensitive to warfarin with 87% activity at 100 m inhibitor. In comparison, the mutation Tyr139Ser Münsterland resistance area. Five animals classified as "susceptible" by BCR were determined heterozygous by showed 57% of wild-type activity in the absence of warfarin but still 33% residual activity at the highest inhibitor ARMS-PCR for the Tyr139Cys mutation. The mutation was confirmed by sequencing in all 5 animals. Thus, concentrations tested. Basal VKOR activity of mutation Tyr139Cys was ‫%84ف‬ of wild type without warfarin and these may be seen as false-negative results of the BCR.
In Denmark, of 58 rats from 24 localities in four 25% at 100 m. The two mutations Leu120Gln and Leu128Gln had initial activities of 50 and 20% of nordifferent regions/islands (Jütland, Zealand, Fünen, Bornholm), 15 were classified "susceptible" and 43 "remal, respectively, and residual activities of 9% each at 100 m warfarin. Substitution of Leu128 by serine sistant" according to BCR or feeding tests (World caused the lowest VKOR activity (17%) and was least Health Organization 1982). All resistant individuals resistant to drug inhibition (3% at 100 m). Both amino showed the Tyr139Cys mutation and all but one of the acid substitutions that were observed in individual wild sensitive individuals were confirmed "wild type" by rats, Arg35Pro and Ser56Pro, nearly abolished VKOR ARMS-PCR. Within this sample, 24 of 31 rats from two activity with Ͻ5% in the absence of warfarin. Upon localities (Horsens, Jütland, and Vordingborg, Zealand) inhibition the activity fell below our detection limit. carried the mutation homozygously; the others showed heterozygous genotypes at position 139.
Recombinant expression and VKOR activity measure-DISCUSSION ments: VKOR activity was measured in HEK293 cells transfected with a series of VKORC1 cDNA constructs Previously, the VKORC1 gene that encodes an essential component of the vitamin K recycling complex was and its inhibition by warfarin was determined ( Figure Figure 2 .-VKORC1 activity after recombinant expression in HEK293 cells. HEK293 cells were transfected by VKORC1 cDNA constructs and enzyme activity was measured as described in materials and methods. Activity of the wild-type construct in the absence of warfarin was set to 100%. All experiments were run in triplicate.
play an even broader spectrum of resistance mutations with a Tyr139Phe mutation prevalent in Belgium and France, Arg35Pro in France, Ser56Pro as a second mutation in Münsterland, and proof of the Tyr139Cys mutation also occurring in England. In particular, the same population. The resistant wild population in Germany (Münsterland, Emsland) appeared genetically rather homogeneous. In this largest field sample 10 identified as the gene responsible for warfarin resistance discordant results between BCR and genotype as asand combined deficiency of vitamin-K-dependent clotsessed by ARMS-PCR were observed. Upon subsequent ting factors in humans (Rost et al. 2004) . The chromosequencing of the entire VKORC1 coding region in the somal position of human VKORC1 is orthologous to the 10 discordant rats, a novel mutation, Ser56Pro, was Rw locus in rats and the War locus in mice (Wallace found in two animals. Thus, of the 286 BCR-positive and MacSwiney 1976; Kohn and Pelz 1999; Fregin et (resistant) rats, 3 had no mutations in VKORC1 and 5 al. 2002) . Thus, VKORC1 was the prime candidate gene of 147 BCR-negative animals were carriers of the Tyr139-for warfarin resistance in rodents as well. In the present Cys mutation. Although it is possible that the 3 "falsestudy, we have identified VKORC1 mutations in all but positive" rats had developed resistance by another mothree warfarin-resistant rodents tested. lecular mechanism, it appears more likely that they Origin of mutations: Apparently, codons 128 and 139 reflect failures of the BCR-a complex in vivo test, which of the VKORC1 gene represent "hotspots" for mutations has proven difficult to standardize. If so, our data allow as two and three mutations, respectively, were identified for a reassessment of sensitivity and specificity of the in two species, rats and mice. Previously, leucine 128 BCR at 0.989 and 0.965, respectively. had been found mutated to arginine in a human patient Migration of rat clans and spread of resistance are resistant to coumarin treatment for thrombosis (Rost well-established observations (Drummond 1966) . It canet al. 2004) . Interestingly, codon usage at these positions not be ruled out that resistant rats have migrated over differs among species and none of the codons contains considerable distances, e.g., from Denmark to Mün-the mutation-prone CpG dinucleotide (Table 2 ). Thus, sterland or vice versa. Alternatively, the present distributhe gene sequence does not provide a straightforward tion of variability in VKORC1 sequence may reflect explanation for the recurrent mutations.
founder effects in species that are relatively new to WestAlthough all laboratory strains carrying Rw or War ern Europe. Although R. rattus has been known in parts were established from single founder individuals, the of Europe for ‫000,01ف‬ years, there is evidence that R. recurrent and independent mutations in VKORC1 make norvegicus may have been imported for the first time it highly unlikely that these reflect neutral sequence into Denmark from Russia in 1716 (Twigg 1975) . Over variation among wild populations of rodents. This is the next 80 years they colonized the whole of Western Europe, but there is no information about whether this reinforced by data from wild-caught animals, which dis- was a spread of rats from Denmark or whether other subset of 12 wild-caught resistant rats from Münsterland, which were shown to be Cys139 homozygotes. At 2 m point importations from eastern countries occurred.
To date, mutations in the VKORC1 gene can be associwarfarin, microsomal VKOR activities varied between 72 and 97% of the uninhibited enzyme preparation ated with warfarin resistance in three species, humans, rats, and mice. The four human resistant patients identi- (Thijssen and Pelz 2001) . This compares well to our in vitro data, given that the HEK system may not comfied to date represent independent mutation events (Rost et al. 2004 ). The present data strongly argue for at prise all the components present in liver (Note that much higher warfarin concentrations are required to least seven independent mutation events in R. norvegicus and two in mice. Taking into account the extensive use inhibit the recombinant enzyme.) All three tyrosine 139 mutations retain higher than wild-type activities in the of anticoagulant compounds over Ͼ50 years, sequence changes appear to be rare spontaneous events. Apparpresence of warfarin even at high concentrations (Figure 2) . In contrast, mutations at arginine 35, serine ently, they confer a tremendous selective advantage in the presence of anticoagulant baits.
56, leucine 120, and leucine 128, respectively, reduced VKORC1 activity to very low basal levels. In the presence Effect of mutations on protein function: Upon recombinant expression in HEK293 cells, all but one of of an inhibitor, activities of the Leu128, Arg35, and Ser56 mutations fell below our detection limit. the amino acid replacements studied reduced VKORC1 activity and conferred warfarin resistance to varying deThe VKORC1 protein is not fully characterized yet and its catalytic site (s) has not yet been determined grees (Figure 2 ). The mutation Tyr139Cys showed 50% of wild-type activity in the absence of warfarin. VKOR experimentally. A multiple sequence alignment of 37 related genes from archaebacteria, eubacteria, and metazoa activity has been measured in liver microsomes from a has identified three to four potential hydrophobic trans-2. Resistance to second generation anticoagulants has been reported for a proportion of resistant indimembrane domains, four cysteines and one serine/ threonine to be fully conserved between species, and a viduals (Rowe et al. 1981; Greaves et al. 1982; MacNicoll and Gill 1987; Johnson 1988) but this can-CXXC motif known from thioredoxin oxidoreductases (Trx) as an electron donor in a variety of reduction not be fully explained by variability in VKORC1 sequence data. It has been suggested that secondary reactions (see Figure 3 ; Goodstadt and Ponting 2004; Rost et al. 2004) . None of these residues is involved in or modifier genes confer resistance to second-generation anticoagulants in rats that carry the Rw gene any of the known mutations, but serine 56 immediately precedes the conserved serine/threonine at position 57. (Greaves and Cullen-Ayres 1988; Kohn and Pelz 1999) . However, so far all attempts to map the resisThe mutation hotspot at tyrosine139 is part of the hydrophobic sequence motif Thr-Tyr-Ala, which is also tance gene(s) for difenacoum or bromadiolone by cross-breeding experiments have failed to identify a found in another dicoumarol and warfarin-sensitive single Mendelian locus for the trait(s) (Greaves and quinone oxidoreductase (NQOR, E.C. 1.6.99.2, preCullen-Ayres 1988; A. D. MacNicoll, unpublished viously also known as DT-diaphorase; Hall et al. 1972) . data). Although in recombinant expression systems, In NQOR, this tyrosine has been identified as the di-VKORC1 alone is capable of reducing vitamin K-2,3-coumarol binding site by photoaffinity labeling and epoxide in a warfarin-sensitive manner (Figure 2 ; Li site-directed mutagenesis (Ma et al. 1992) . Given its et al. 2004; Rost et al. 2004) , it has long been postuinvolvement in three mutation events conferring warfalated that the enzyme may be part of a larger complex rin resistance, it is tempting to predict that Tyr139 may in liver microsomes (Cain et al. 1997) . In addition, also be part of the warfarin-binding site in VKORC1.
variation in anticoagulant uptake, metabolism, and In the HEK cell system, mutations affecting other clearance may influence the efficacy of rodenticides amino acid residues have very low enzyme activities in vivo. Further experiments will address the question even in the absence of warfarin. If this were to reflect whether VKORC1 is sensitive to second-generation the situation in vivo, it is hard to conceive how animals anticoagulants. could generate sufficient vitamin KH 2 for effective gamma-carboxylation and clotting activity. Given the Rodenticide resistance testing: In this study, we have great selective pressure of warfarin poisoning, the funcidentified mutations in the VKORC1 gene sequence that tional elimination of VKORC1 by mutation may boost correlate very well with the results from BCR tests for the upregulation of other pathways for the recruitment warfarin resistance but less well with resistance to secof vitamin KH 2 . Thus, warfarin resistance could be conond-generation anticoagulants. BCR tests require that ferred by knocking down VKORC1 activity while switchrats or mice are trapped alive, transported to a central ing to another warfarin-insensitive pathway would secure facility, and subjected to anticoagulant administration effective blood clotting for survival. That such compenand blood sampling, which requires ethical approval satory mechanisms may be involved is suggested by the and licensing in most countries. We have demonstrated differences observed in dietary vitamin K requirements that a PCR-based genetic test for mutations in the for some resistant laboratory strains (Bell and Cald- VKORC1 gene can successfully identify warfarin-resistant well 1973; MacNicoll 1985; Thijssen 1995). The two rats trapped in the field. This test could readily be apBerkshire strains (maintained at CSL, York, and Readplied to tissue from dead rodents and potentially to ing University, respectively) have the same mutation as host genetic material sloughed off onto fecal pellets, the Hampshire strain (Leu120Gln), but only the Berkproviding a totally noninvasive sampling procedure. shire colony at Reading has an increased dietary vitamin This genetic test will provide a simpler, and potentially K requirement that is comparable with that of the Hampcheaper, method for monitoring the distribution of warshire strain. Furthermore, the Scottish (Leu128Gln) and farin-resistant rats and mice and for evaluating the imthe Münsterland strains (Tyr139Cys) require low substitupact of strategies to manage and overcome resistance. tion levels whereas the Welsh strain (Tyr139Ser) is depenThe authors thank Dagmar Funck, Engelbert Kampling, Ralf dent on high supplementation doses. dress this question.
